Immunovant, Inc. (IMVT) Securities Fraud Investigation - Levi & Korsinsky

NEW YORK CITY, NY / ACCESS Newswire / September 25, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Immunovant, Inc. ("Immunovant, Inc.") (NASDAQ:IMVT) concerning potential violations of the federal securities laws.

Immunovant, Inc. shares fell 7.37% on September 23, 2026, after the company announced that its proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus failed to meet its primary endpoint. Following the disappointing results, the company decided to discontinue the development of the drug for this indication. The setback is particularly significant because IMVT-1402 had recently become Immunovant's lead development asset.

If you suffered a loss on your Immunovant, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP